Heron Therapeutics Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more
Heron Therapeutics Inc. (0J4V) - Total Liabilities
Latest total liabilities as of December 2025: $656.54 Million USD
Based on the latest financial reports, Heron Therapeutics Inc. (0J4V) has total liabilities worth $656.54 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Heron Therapeutics Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how Heron Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Heron Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Heron Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MacroGenics Inc
NASDAQ:MGNX
|
USA | $203.76 Million |
|
Maider Medical Industry Equipment Co Ltd
SHG:688310
|
China | CN¥357.60 Million |
|
Motorpoint Group plc
PINK:MTPTF
|
USA | $166.70 Million |
|
Senao Networks
TWO:3558
|
Taiwan | NT$6.45 Billion |
|
Franklin Covey Company
NYSE:FC
|
USA | $167.25 Million |
|
Beacon Minerals Limited
AU:BCN
|
Australia | AU$45.74 Million |
|
GOME Retail Holdings Limited
PINK:GMELF
|
USA | $42.20 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Heron Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 45.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heron Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heron Therapeutics Inc. (2012–2025)
The table below shows the annual total liabilities of Heron Therapeutics Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $656.54 Million | +146.08% |
| 2024-12-31 | $266.80 Million | +4.02% |
| 2023-12-31 | $256.48 Million | +8.05% |
| 2022-12-31 | $237.38 Million | +4.05% |
| 2021-12-31 | $228.14 Million | +94.88% |
| 2020-12-31 | $117.06 Million | +7.45% |
| 2019-12-31 | $108.95 Million | +18.40% |
| 2018-12-31 | $92.02 Million | -10.81% |
| 2017-12-31 | $103.17 Million | +16.27% |
| 2016-12-31 | $88.73 Million | +349.62% |
| 2015-12-31 | $19.73 Million | +44.90% |
| 2014-12-31 | $13.62 Million | +94.79% |
| 2013-12-31 | $6.99 Million | +68.32% |
| 2012-12-31 | $4.15 Million | -- |